BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
The role of short-chain fatty acids in microbiota-gut-brain communication. ✅
Go to Publication ✅
Nature reviews. Gastroenterology & hepatology (Nat Rev Gastroenterol Hepatol ) Vol: 16 Issue 8 Pages: 461-478 Pub: 2019 Aug Epub: Authors Dalile B , Van Oudenhove L , Vervliet B , Verbeke K , |
|
|
Effect of fucoidan on ethanol-induced liver injury and steatosis in mice and the underlying mechanism. ✅
Go to Publication ✅
Food & nutrition research (Food Nutr Res ) Vol: 65 Issue Pages: Pub: 2021 Epub: 2021 Apr 20 Authors Xue M , Liang H , Zhou Z , Liu Y , He X , Zhang Z , Sun T , Yang J , Qin Y , Qin K , |
|
|
Effects of seaweed extracts on in vitro rumen fermentation characteristics, methane production, and microbial abundance. ✅
Go to Publication ✅
Scientific reports (Sci Rep ) Vol: 11 Issue 1 Pages: 24092 Pub: 2021 Dec 16 Epub: 2021 Dec 16 Authors Choi Y , Lee SJ , Kim HS , Eom JS , Jo SU , Guan LL , Seo J , Kim H , Lee SS , Lee SS , |
|
|
A comparative study of the effects of different fucoidans on cefoperazone-induced gut microbiota disturbance and intestinal inflammation. ✅
Go to Publication ✅
Food & function (Food Funct ) Vol: 12 Issue 19 Pages: 9087-9097 Pub: 2021 Oct 4 Epub: 2021 Oct 4 Authors Luo J , Wang Z , Fan B , Wang L , Liu M , An Z , Zhao X , |
|
|
Sargassum fusiforme fucoidan modifies gut microbiota and intestinal metabolites during alleviation of hyperglycemia in type 2 diabetic mice. ✅
Go to Publication ✅
Food & function (Food Funct ) Vol: 12 Issue 8 Pages: 3572-3585 Pub: 2021 Apr 26 Epub: Authors Wu Q , Wu S , Cheng Y , Zhang Z , Mao G , Li S , Yang Y , Zhang X , Wu M , Tong H , |
|
|
Correction: Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance of Lactobacillus and Ruminococcaceae. ✅
Go to Publication ✅
Food & function (Food Funct ) Vol: 9 Issue 1 Pages: 655 Pub: 2018 Jan 24 Epub: Authors Shang Q , Shan X , Cai C , Hao J , Li G , Yu G , |
|
|
The Effect of Increasing Inclusion Levels of a Fucoidan-Rich Extract Derived from Ascophyllum nodosum on Growth Performance and Aspects of Intestinal Health of Pigs Post-Weaning. ✅
Go to Publication ✅
Marine drugs (Mar Drugs ) Vol: 17 Issue 12 Pages: Pub: 2019 Nov 30 Epub: 2019 Nov 30 Authors Rattigan R , Sweeney T , Vigors S , Thornton K , Rajauria G , O'Doherty AJV , |
|
|
Fucoidan from Undaria pinnatifida Enhances Exercise Performance and Increases the Abundance of Beneficial Gut Bacteria in Mice. ✅
Go to Publication ✅
Marine drugs (Mar Drugs ) Vol: 22 Issue 11 Pages: Pub: 2024 Oct 29 Epub: 2024 Oct 29 Authors Yang C , Dwan C , Wimmer BC , Wilson R , Johnson L , Caruso V , |
|
|
Low molecular fucoidan alleviated alcohol-induced liver injury in BALB/c mice by regulating the gut microbiota-bile acid-liver axis. ✅
Go to Publication ✅
International journal of biological macromolecules (Int J Biol Macromol ) Vol: 282 Issue Pt 3 Pages: 136930 Pub: 2024 Dec Epub: 2024 Oct 28 Authors Sun Y , Men Q , Ren X , Yan C , Song S , Ai C , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
